Therefore, it is reasonable to assume that suramin may be considered a pharmacological agent modifying the activity of the VEGF-A/VEGFR axis, which may be used in research on the potential role of VEGF-A in the pathogenesis of renal vascular complications in the course of short-term diabetes. The gene discussed is VEGFA; the disease is diabetes mellitus.